Published on

Rhode Island Sues Teva and Allergan for Fueling State Opioid Epidemic

The Rhode Island Attorney General Peter Neronha has settled over $100 million with Teva and Allergan pharmaceutical companies.

On Monday, Neronha filed a lawsuit against two big drug manufacturers for their contribution to the opioid epidemic in Rhode Island. The settlement includes $28.5 million in cash between Teva and Allergan, plus 1 million of Naloxone sprays and 67,000 Suboxone units. Both Naloxone and Suboxone help patients prevent possible opioid addiction.

Neronha claimed, “While no amount of money will ever be enough to undo the harm suffered by Rhode Islanders throughout the ongoing opioid epidemic, these additional recoveries will further support public health efforts to respond to the challenges brought on by this epidemic.”

The spokespersons of Teva Pharmaceutical Industries called the settlement “a critical step forward in getting life-saving treatments to the people who need them.”

Also read:US House Voted to End Trade Relations with Russia and Belarus

In a 424-8 vote, the US House of Representatives passed a bill to suspend normal trade relations with Russia and Belarus. If the Se...

Previously, in February 2021, the Rhode Island Attorney General sued McKinsey & Co. for $2.59 million for its assistance in broad anti-opioid drug promotion and gaining profit from the opioid crisis.

Article by Yevheniia Savchenko

Yevheniia Savchenko is a Product Content Manager at Lawrina. Yevheniia creates user interface copies for Lawrina products, writes release notes, and helps customers get the best user experience from all Lawrina products. Also, Yevheniia is in charge of creating helpful content on legal template pages (Lawrina Templates) and up-to-date information on US law (Lawrina Guides). In her spare time, Yevheniia takes up swimming, travels, and goes for a walk in her home city.

Thank You! Welcome on board
We use cookies to improve our website's work and deliver better services.
Our use of cookies
Upgrade the manual re-reading of agreements with Loio's AI-driven Highlights. Be in full control over every editing decision, but have the power of machine learning analysis by your hand. Turn on the Highlights tool whenever you need an extra check of your document's most essential details.
These cookies collect information that is used to help Us understand how Our Site are being used or how effective Our marketing campaigns are, or to help Us customize Our Site for You. We use Google Analytics to recognize You and link the devices You use when You visit Our Site or Service on Your browser or mobile device, login to Your User Account on Our Site, or otherwise engage with Us.
Communication services
These cookies collect information that is used to help Us to facilitate the interaction with You on Our Site. We also use those cookies to improve customer service by maintaining contact with visitors of Our Site through Intercom chat.
Ad Services
We and Our third-party partners may also use cookies and tracking technologies for advertising purposes. These third-party services collect information about Your use of Our Site over time so that they may play or display ads on devices You may use, and on other websites, apps, or services.